Evidence map›Paper›PMID 38675483›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Overview of Research on Leishmaniasis in Africa: Current Status, Diagnosis, Therapeutics, and Recent Advances Using By-Products of the Sargassaceae Family.

Fatouma Mohamed Abdoul-Latif, Khadija Oumaskour, Nadira Abdallah, Ayoub Ainane, Ibrahim Houmed Aboubaker, Ali Merito, Houda Mohamed, Tarik Ainane

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fatouma Mohamed Abdoul-LatifInstitut Supérieur des Sciences de la Santé (ISSS), Djibouti City P.O. Box 2530, Djibouti.ORCID 0000-0001-7213-4700
Khadija OumaskourSuperior School of Technology of Khenifra, University of Sultan Moulay Slimane, P.O. Box 170, Khenifra 54000, Morocco.
Nadira AbdallahInstitut Supérieur des Sciences de la Santé (ISSS), Djibouti City P.O. Box 2530, Djibouti.
Ayoub AinaneSuperior School of Technology of Khenifra, University of Sultan Moulay Slimane, P.O. Box 170, Khenifra 54000, Morocco.ORCID 0000-0002-5004-6416
Ibrahim Houmed AboubakerPeltier Hospital of Djibouti, Djibouti City P.O. Box 2123, Djibouti.
Ali MeritoMedicinal Research Institute, Center for Studies and Research of Djibouti, IRM-CERD, Route de l'Aéroport, Haramous, Djibouti City P.O. Box 486, Djibouti.
Houda MohamedPeltier Hospital of Djibouti, Djibouti City P.O. Box 2123, Djibouti.
Tarik AinaneSuperior School of Technology of Khenifra, University of Sultan Moulay Slimane, P.O. Box 170, Khenifra 54000, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis in Africa, which has been designated as a priority neglected tropical disease by various global organizations, exerts its impact on millions of individuals, primarily concentrated within this particular region of the world. As a result of the progressively grave epidemiological data, numerous governmental sectors and civil organizations have concentrated their endeavors on this widespread outbreak with the objective of devising appropriate remedies. This comprehensive examination delves into multiple facets of this parasitic ailment, scrutinizing the associated perils, diagnostic intricacies, and deficiencies within the existing therapeutic protocols. Despite the established efficacy of current treatments, they are not immune to deleterious incidents, particularly concerning toxicity and the emergence of parasitic resistance, thus accentuating the necessity of exploring alternative avenues. Consequently, this research not only encompasses conventional therapeutic approaches, but also extends its scope to encompass complementary and alternative medicinal techniques, thereby striving to identify innovative solutions. A particularly auspicious dimension of this study lies in the exploration of natural substances and by-products derived from some brown algae of the

Indexed as

Africadiagnosisleishmaniasisnatural productSargassaceaetreatment

Identifiers

PMID38675483
PMCPMC11054980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.